Van Den Bergh Annelies, Bailly Benjamin, Guillon Patrice, von Itzstein Mark, Dirr Larissa
Institute for Glycomics, Griffith University, Gold Coast, Queensland, Australia.
J Virol. 2024 Jun 13;98(6):e0164123. doi: 10.1128/jvi.01641-23. Epub 2024 May 1.
Numerous viruses have been found to exploit glycoconjugates expressed on human cells as their initial attachment factor for viral entry and infection. The virus-cell glycointeractome, when characterized, may serve as a template for antiviral drug design. Heparan sulfate proteoglycans extensively decorate the human cell surface and were previously described as a primary receptor for human metapneumovirus (HMPV). After respiratory syncytial virus, HMPV is the second most prevalent respiratory pathogen causing respiratory tract infection in young children. To date, there is neither vaccine nor drug available to prevent or treat HMPV infection. Using a multidisciplinary approach, we report for the first time the glycointeractome of the HMPV fusion (F) protein, a viral surface glycoprotein that is essential for target-cell recognition, attachment, and entry. Our glycan microarray and surface plasmon resonance results suggest that Galβ1-3/4GlcNAc moieties that may be sialylated or fucosylated are readily recognized by HMPV F. The bound motifs are highly similar to the -linked and linked glycans primarily expressed on the human lung epithelium. We demonstrate that the identified glycans have the potential to compete with the cellular receptors used for HMPV entry and consequently block HMPV infection. We found that lacto--neotetraose demonstrated the strongest HMPV binding inhibition in a cell infection assay. Our current findings offer an encouraging and novel avenue for the design of anti-HMPV drug candidates using oligosaccharide templates.IMPORTANCEAll cells are decorated with a dense coat of sugars that makes a sugar code. Many respiratory viruses exploit this sugar code by binding to these sugars to cause infection. Human metapneumovirus is a leading cause for acute respiratory tract infections. Despite its medical importance, there is no vaccine or antiviral drug available to prevent or treat human metapneumovirus infection. This study investigates how human metapneumovirus binds to sugars in order to more efficiently infect the human host. We found that human metapneumovirus binds to a diverse range of sugars and demonstrated that these sugars can ultimately block viral infection. Understanding how viruses can take advantage of the sugar code on our cells could identify new intervention and treatment strategies to combat viral disease.
已发现许多病毒利用人类细胞上表达的糖缀合物作为其病毒进入和感染的初始附着因子。对病毒 - 细胞糖相互作用组进行表征后,可为抗病毒药物设计提供模板。硫酸乙酰肝素蛋白聚糖广泛修饰人类细胞表面,此前被描述为人偏肺病毒(HMPV)的主要受体。在呼吸道合胞病毒之后,HMPV是导致幼儿呼吸道感染的第二大常见呼吸道病原体。迄今为止,尚无预防或治疗HMPV感染的疫苗或药物。我们采用多学科方法,首次报道了HMPV融合(F)蛋白的糖相互作用组,该病毒表面糖蛋白对于靶细胞识别、附着和进入至关重要。我们的聚糖微阵列和表面等离子体共振结果表明,可能被唾液酸化或岩藻糖基化的Galβ1 - 3/4GlcNAc部分很容易被HMPV F识别。结合的基序与主要在人肺上皮细胞上表达的O - 连接和N - 连接聚糖高度相似。我们证明,所鉴定的聚糖有可能与用于HMPV进入的细胞受体竞争,从而阻断HMPV感染。我们发现乳糖 - N - 新四糖在细胞感染试验中表现出最强的HMPV结合抑制作用。我们目前的研究结果为使用寡糖模板设计抗HMPV候选药物提供了一条令人鼓舞的新途径。
所有细胞都被一层密集的糖衣所覆盖,形成了一种糖代码。许多呼吸道病毒通过与这些糖结合来利用这种糖代码引发感染。人偏肺病毒是急性呼吸道感染的主要原因。尽管其具有医学重要性,但尚无预防或治疗人偏肺病毒感染的疫苗或抗病毒药物。本研究调查了人偏肺病毒如何与糖结合以便更有效地感染人类宿主。我们发现人偏肺病毒与多种糖结合,并证明这些糖最终可阻断病毒感染。了解病毒如何利用我们细胞上的糖代码,可为对抗病毒性疾病确定新的干预和治疗策略。